Clinical Trial Update: Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluated erlotinib as neoadjuvant and adjuvant therapy around surgery for muscle-invasive bladder cancer; the study has completed and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Bladder Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-06-19